Thymosin Alpha1

DRUG9 trials

Sponsors

Wen-hong Zhang, RenJi Hospital, Sun Yat-sen University, Fudan University, Nanjing Medical University

Conditions

Cardiopulmonary BypassChronic Hepatitis bImmunotherapyIrAELong-term Effects of Thymosin Alpha 1 TreatmentNon Small Cell Lung CancerNon-small Cell Lung CancerOsteoporotic Pain

Phase 2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Active, not recruitingNCT06139419

Sun Yat-sen UniversityNon-small Cell Lung Cancer

Start: 2023-07-25End: 2026-08-30Updated: 2025-11-17

Thymosin-α1 for Recurrent Implantation Failure

RecruitingNCT07675980

Fakih IVF Fertility CenterRecurrent Implantation Faliure

Start: 2026-02-11End: 2027-06-01Target: 136Updated: 2026-06-30

Phase 3

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

RecruitingNCT05086614

Fudan UniversityStage II Colorectal Cancer, Stage III Colorectal Cancer

Start: 2021-04-01End: 2027-03-31Target: 2500Updated: 2021-10-21

Phase 4

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Wen-hong ZhangChronic Hepatitis b

Start: 2017-10-25End: 2018-12-30Target: 240Updated: 2018-02-28

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

RenJi HospitalOsteoporotic Pain

Start: 2020-11-01End: 2021-12-31Target: 100Updated: 2020-08-26

Thymosin Alpha-1 for irAE Secondary to ICIs

Start: 2023-09-01End: 2025-04-30Target: 40Updated: 2023-12-20

Unknown Phase

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Not yet recruitingNCT04901104

Sun Yat-sen UniversityLong-term Effects of Thymosin Alpha 1 Treatment

Start: 2021-07-01End: 2027-03-31Target: 900Updated: 2021-05-25

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Nanjing Medical UniversityCardiopulmonary Bypass, Immunotherapy, Rheumatic Heart Disease

Start: 2022-07-01End: 2023-12-31Target: 200Updated: 2022-08-04

Immuno-effect of Tα1 for Stage I NSCLC

RecruitingNCT06598839

Yousheng MaoNon Small Cell Lung Cancer

Start: 2024-06-30End: 2025-12-30Target: 40Updated: 2024-09-19